Globus Medical Q2 net sales $292M (+10.6% YoY); raises FY 2023 guidance to $1.125B

GLOBUS MEDICAL INC

2023-Q2 EPS reported $1.05 revenue$568,303,000

Net sales $291.6M, up 10.6% YoY; GAAP net income $57.7M (+5.7%).
GAAP diluted EPS $0.57; non-GAAP diluted EPS $0.63 (+12.3%).
Non-GAAP adjusted EBITDA $96.1M (33.0% of sales).
Raised FY 2023 net sales guidance to $1.125B (from $1.100B); reaffirmed non-GAAP EPS $2.30.
Launched REFLECT Scoliosis Correction System and MARVEL Growing Rod System.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.75

GLOBUS MEDICAL INC updated its three-month period ended June 30, 2023 guidance (raised).

Period: three-month period ended June 30, 2023
Guidance: raised
Result: reported results

Exact text from the filing

On August 3, 2023, we issued a press release reporting, among other things, our sales and operating results for the three-month period ended June 30, 2023.

View on SEC.gov

Browse all earnings releases →

GLOBUS MEDICAL INC filing history →

Source: SEC EDGAR

accession 0001562762-23-000305

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.